Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment ...

Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, ...

Subcutaneous immunotherapy injections for cancer are given using a needle and a syringe. A doctor or oncological nurse inserts the needle into the space between the skin and muscle.

The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...

The injection process is expected to take just 15 seconds, on average. Patients would have to start with biweekly IV infusions and then would have the option to switch to a weekly subcutaneous shot.

Panelists discuss how incorporating subcutaneous (SubQ) formulations into clinical formularies requires careful evaluation of clinical equivalence, workflow fit, and reimbursement logistics, with ...

Subcutaneous injectable drugs can be a much quicker process. However, some observation is still typically required after injections, and the actual difference in treatment time may not be all that ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous ...

Injection site reactions to etanercept usually occur within the first month of treatment. They most commonly occur 1 to 2 days after an injection, and the duration is usually 3 to 5 days.

The injection takes just 3-5 min to administer, compared with 30-60 min for the intravenous (IV) infusion. Patients will still attend hospital every 2-4 weeks but will spend significantly less ...

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ...